Immuto Scientific is a platform biotech company pioneering a new era in therapeutic discovery by targeting the once thought 'undruggable' proteins and pathways, bringing hope to millions of patients facing conditions with no cure. Our innovative platform combines cutting-edge technology with deep scientific expertise to unlock novel therapies that traditional methods couldn't reach. The heart of our approach is a powerful structure-based drug discovery engine that enables high throughput characterization of protein structures in live cells to identify novel drug targets that are highly disease-specific protein conformations. With our leading-edge platforms, we develop best-in-class therapeutics with exceptional safety and efficacy profiles. We have a preclinical internal pipeline of oncology assets and we partner with companies in multiple different disease areas.